The hearing will focus on the outrageously high cost of Ozempic and Wegovy 

WASHINGTON, June 24 – Sen. Bernie Sanders (I-Vt.), Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), announced today that Novo Nordisk CEO Lars Jørgensen will be testifying before the committee on Tuesday, September 24 at 10 a.m. ET. The hearing will focus on the outrageously high prices that Novo Nordisk charges Americans for their blockbuster drugs, Ozempic and Wegovy.  

“I look forward to the CEO of Novo Nordisk testifying before the HELP Committee on the outrageously high costs of Ozempic and Wegovy in the United States,” said Chairman Sanders. “The American people are sick and tired of paying, by far, the highest prices in the world for prescription drugs. Novo Nordisk currently charges Americans with Type 2 diabetes $969 a month for Ozempic, while this same exact drug can be purchased for just $155 in Canada, $122 in Denmark, and just $59 in Germany. Incredibly, Novo Nordisk also charges Americans with obesity $1,349 a month for Wegovy, while this same exact product can be purchased for just $186 in Denmark, $140 in Germany, and $92 in the United Kingdom. The Committee looks forward to Mr. Jørgensen answering a very simple question: Why does he think it’s acceptable to charge Americans up to 10 or 15 times more for Ozempic and Wegovy than people in Europe and other major countries?”